title: Can HER2 overexpression predict response to pegylated liposomal doxorubicin in metastatic breast cancer patients?
authors.forename: A
authors.initials: A
authors.lastname: Fabi
authors.forename: G
authors.initials: G
authors.lastname: Ferretti
authors.forename: N
authors.initials: N
authors.lastname: Salesi
authors.forename: P
authors.initials: P
authors.lastname: Papaldo
authors.forename: P
authors.initials: P
authors.lastname: Carlini
authors.forename: M
authors.initials: M
authors.lastname: Ciccarese
authors.forename: B
authors.initials: B
authors.lastname: Di Cocco
authors.forename: F
authors.initials: F
authors.lastname: Cecere
authors.forename: C
authors.initials: C
authors.lastname: Nardoni
authors.forename: A
authors.initials: A
authors.lastname: Felici
authors.forename: F
authors.initials: F
authors.lastname: Cognetti
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011237:Predictive Value of Tests; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis*; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D014408:Biomarkers, Tumor; D004317:Doxorubicin; D018719:Erb-b2 Receptor Tyrosine Kinases